LIDEX
LOE ApproachingNDATOPICALSOLUTION
Approved
Apr 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIDEX is a topical solution small-molecule product approved in 1984 for dermatological indications. The generic name and specific mechanism of action are not publicly detailed in available records. It represents a mature, established therapeutic option in the topical steroid or anti-inflammatory space.
LOE Approaching
Product is in late-stage maturity with approaching loss of exclusivity; commercial teams likely focused on defending market share and planning transition strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LIDEX offers experience in late-lifecycle product management, competitive defense, and transition planning. Roles are likely focused on margin protection, generic preparation, and organizational efficiency rather than growth.
Brand ManagerField Sales Representative
Worked on LIDEX at Alvogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.